Articles producció científica> Medicina i Cirurgia

SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma

  • Datos identificativos

    Identificador: imarina:2309057
    Autores:
    Rueda Domínguez, AntonioAlfaro Lizaso, JCruz Merino, L de laGumà Padró, JosepQuero Blanco, CristinaGómez Codina, JoséLlanos Muñoz, MartaMartínez Banaclocha, NatividadRodríguez Abreu, DelvysProvencio Pulla, Mariano
    Resumen:
    Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT.
  • Otros:

    Autor según el artículo: Rueda Domínguez, Antonio; Alfaro Lizaso, J; Cruz Merino, L de la; Gumà Padró, Josep; Quero Blanco, Cristina; Gómez Codina, José; Llanos Muñoz, Marta; Martínez Banaclocha, Natividad; Rodríguez Abreu, Delvys; Provencio Pulla, Mariano
    Departamento: Medicina i Cirurgia
    Autor/es de la URV: Gumà Padró, José
    Palabras clave: Hashtag Etiqueta «#» @uroweb @residentesaeu @infoAeu
    Resumen: Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT.
    Áreas temáticas: Saúde coletiva Oncology Odontología Medicine (miscellaneous) Medicina veterinaria Medicina ii Medicina i Farmacia Engenharias ii Ciências biológicas ii Ciências biológicas i Cancer research Biotecnología
    Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 1699048X
    Direcció de correo del autor: jose.guma@urv.cat
    Identificador del autor: 0000-0001-7541-9832
    Fecha de alta del registro: 2024-09-07
    Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
    Enlace a la fuente original: https://pubmed.ncbi.nlm.nih.gov/26497354/
    URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referencia al articulo segun fuente origial: Clinical & Translational Oncology. 17 (12): 1005,1013-1013
    Referencia de l'ítem segons les normes APA: Rueda Domínguez, Antonio; Alfaro Lizaso, J; Cruz Merino, L de la; Gumà Padró, Josep; Quero Blanco, Cristina; Gómez Codina, José; Llanos Muñoz, Marta; (2015). SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma. Clinical & Translational Oncology, 17(12), 1005,1013-1013
    DOI del artículo: 10.1007/s12094-015-1429-1
    Entidad: Universitat Rovira i Virgili
    Año de publicación de la revista: 2015
    Tipo de publicación: Journal Publications
  • Palabras clave:

    Cancer Research,Medicine (Miscellaneous),Oncology
    Saúde coletiva
    Oncology
    Odontología
    Medicine (miscellaneous)
    Medicina veterinaria
    Medicina ii
    Medicina i
    Farmacia
    Engenharias ii
    Ciências biológicas ii
    Ciências biológicas i
    Cancer research
    Biotecnología
  • Documentos:

  • Cerca a google

    Search to google scholar